Cabometyx Improves Survival Without Progression in Previously Treated Advanced NETs

Patients with previously treated advanced neuroendocrine tumors who received treatment with Cabometyx had improved progression-free survival compared with placebo.

Related Keywords

Dana Farber Cancer Institute ,Massachusetts ,United States ,Boston ,Jennifera Chan , ,Harvard Medical School ,Neuroendocrine Tumors At Dana Farber Cancer Institute ,National Cancer Institute ,Gastrointestinal Cancer Center ,Program In Carcinoid ,National Cancer ,Neuroendocrine Tumors ,News ,Tumors ,